Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26110395 | 0.96 | HSD17B10 (0.44) | HSD17B10ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL22289913 | 0.82 | GFER (0.46) | HSD17B10ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL7532325 | 0.78 | HCAR2 (0.36) | HSD17B10ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL19140344 | 0.77 | USP2 (0.45) | HSD17B10ALDH1A1KMT2AMAPTUSP2 | |
| SCHEMBL2114253 | 0.74 | KDM4E (0.45) | HSD17B10ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL23937644 | 0.73 | ALDH1A1 (0.40) | HSD17B10ALOX15CASP1CASP7ALDH1A1 | |
| SCHEMBL7394232 | 0.73 | ALDH1A1 (0.39) | HSD17B10ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL22289985 | 0.73 | MAPT (0.54) | HSD17B10ALOX15MAPK1ALDH1A1KMT2A | |
| SCHEMBL22289963 | 0.73 | CXCR2 (0.36) | HSD17B10ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL7435029 | 0.73 | BTK (0.34) | HSD17B10ALOX15MAPK1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | claimed |
| WO-2008148034-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-04 | — | — | WO | claimed |
| EP-1210328-A1 | FUSED PYRROLECARBOXAMIDES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001016103-A1 | FUSED PYRROLECARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2001-03-08 | — | — | WO | claimed |
| CN-115969814-A | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | 法斯瑞斯公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3600259-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | Phosphorex, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183631-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | PHOSPHOREX, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2008148034-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | HSD17B10 265/4885ALOX15 440/4885MAPK1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.